Peptide Calculator
Vial and water math for Semaglutide, with a research record of published human trials. Math only, no suggested amounts.
Compound (Optional)
Desired Amount Per Dose
IU measures activity, not weight, so 1 IU is never treated as 1 mcg. The math below uses the vial’s own IU count.
Vial Strength (Total mg of Your Vial)
Reconstitution Solution Added
Titration Schedule (Optional)
Saved as this peptide’s dose schedule. You can change it in Schedule & Log.
Holds automatically at this dose.
Keeps going up on schedule. Tap Hold at This Dose when you get there.
Not knowing is normal. Everyone is different, and the app will help guide you as needed.
You set every number here. PeptideWhiz doesn’t suggest a plan. This is what gets saved, and it’s what your log header and printed schedule show.
About Semaglutide
Semaglutide is a long-acting analogue of the gut hormone GLP-1 (glucagon-like peptide-1). It binds the GLP-1 receptor, which is involved in insulin release after meals, stomach emptying and appetite signalling. A fatty side chain lets it bind albumin in the blood, which is why trials give it once a week rather than daily.
Research status
Semaglutide is the active ingredient in FDA-approved prescription medicines (Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management). It remains one of the most studied compounds in metabolic research, with trials in diabetes, obesity, heart, kidney and liver outcomes.
How the math works for any vial (concentration, U-100 units, mg and mcg) is explained step by step on the main peptide reconstitution calculator page. Read the full What is Semaglutide? guide for mechanism, trials and conditions researched.
What published studies used
Research record, not a recommendation or protocol
These are published human trials of Semaglutide from the PeptideWhiz study library. The last column quotes each study’s PubMed abstract word for word, so it shows what that study reported giving its participants under medical supervision. It is not advice, and the calculator never fills these numbers in on its own: you can copy one only by tapping its button and confirming.
| Study | Year | Journal | As reported in the abstract | PubMed |
|---|---|---|---|---|
| Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial. | 2026 | The lancet. Diabetes & endocrinology | “Adults with a BMI of 24-<28 kg/m2 and at least one weight-related comorbidity, or a BMI of 28-<30 kg/m2, with or without type 2 diabetes, were randomly assigned (2:1) to once-weekly subcutaneous semaglutide 2·4 mg or placebo, plus lifestyle intervention, for 44 weeks.” | PMID 42575111 |
| Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial. | 2026 | Diabetes, obesity & metabolism | “In Period 1, participants are randomized 2:1 (open label) for 26 weeks to semaglutide and insulin (uptitrated to 1.0 mg weekly) or standard insulin therapy.” | PMID 42473259 |
| Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. | 2026 | The American journal of clinical nutrition | “This 60-wk, double-blind trial randomly assigned 120 adults with overweight/obesity in a 3:2 ratio to semaglutide 2.4 mg or placebo.” | PMID 42323166 |
| Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial. | 2026 | Clinical journal of the American Society of Nephrology : CJASN | “Participants were randomized to 24 weeks of semaglutide 2.4 mg/wk subcutaneously or matched placebo treatment.” | PMID 42308057 |
| Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. | 2026 | The lancet. Diabetes & endocrinology | “The primary endpoint was change in HbA1c from baseline to week 68 with cagrilintide-semaglutide (2·4 mg each) versus semaglutide 2·4 mg in the full analysis set; safety was assessed in all participants who received at least one dose of study product.” | PMID 42251859 |
Disclaimer: this table is an educational research record. It does not recommend, suggest or endorse any amount, schedule or use, and it is not medical advice. Decisions about any medicine belong with a licensed clinician.
Semaglutide calculator FAQ
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist. Semaglutide is a long-acting analogue of the gut hormone GLP-1 (glucagon-like peptide-1).
Is Semaglutide approved?
Semaglutide is the active ingredient in FDA-approved prescription medicines (Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management). It remains one of the most studied compounds in metabolic research, with trials in diabetes, obesity, heart, kidney and liver outcomes.
Does this page suggest a Semaglutide dose?
No. The calculator dose field starts empty and PeptideWhiz never suggests, recommends or calculates an amount for anyone. The study table is a research record of what published trials reported, not a recommendation or protocol.
Where do the study numbers on this page come from?
Each row quotes the abstract of a published human trial (5 trials, 2026 to 2026) word for word, as indexed in PubMed, with a link to the PubMed record. Nothing is rounded, combined or converted.
How does the calculator work with a Semaglutide vial?
Pick Semaglutide in step 1 if you want it on your result card, then enter the vial amount printed on your own label and the water volume actually added. The tool divides one by the other for concentration and shows the matching U-100 syringe units for an amount you type. Pens and pre-filled syringes are already in liquid form and are not reconstituted.
Sources
Study rows: PubMed records linked in the table (abstracts checked against PubMed on October 31, 2026). Unit math: see the sources on the main calculator.
Reviewed by the PeptideWhiz team on October 31, 2026. For research and education only.